Foyston Gordon & Payne Inc Sells 565 Shares of Becton, Dickinson and Company (NYSE:BDX)

Foyston Gordon & Payne Inc lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 47,007 shares of the medical instruments supplier’s stock after selling 565 shares during the quarter. Becton, Dickinson and Company makes up approximately 2.8% of Foyston Gordon & Payne Inc’s portfolio, making the stock its 13th biggest holding. Foyston Gordon & Payne Inc’s holdings in Becton, Dickinson and Company were worth $10,664,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. E. Ohman J or Asset Management AB raised its holdings in Becton, Dickinson and Company by 13.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock valued at $39,951,000 after acquiring an additional 20,859 shares during the period. Busey Bank lifted its position in shares of Becton, Dickinson and Company by 3.8% during the fourth quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock worth $15,031,000 after acquiring an additional 2,399 shares in the last quarter. ORG Partners LLC boosted its holdings in shares of Becton, Dickinson and Company by 689.4% in the fourth quarter. ORG Partners LLC now owns 3,205 shares of the medical instruments supplier’s stock worth $727,000 after acquiring an additional 2,799 shares during the period. Finally, Swedbank AB grew its position in shares of Becton, Dickinson and Company by 1.0% in the fourth quarter. Swedbank AB now owns 152,293 shares of the medical instruments supplier’s stock valued at $34,551,000 after purchasing an additional 1,455 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the sale, the director now owns 36,033 shares in the company, valued at $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 479 shares of the firm’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president now directly owns 4,887 shares of the company’s stock, valued at approximately $964,107.36. This represents a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,578 shares of company stock worth $795,986. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.4 %

BDX opened at $167.22 on Friday. The business’s fifty day simple moving average is $208.84 and its 200 day simple moving average is $223.15. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The stock has a market cap of $48.01 billion, a PE ratio of 27.78, a P/E/G ratio of 1.63 and a beta of 0.31.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the business earned $3.17 earnings per share. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has authorized a stock buyback plan on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.49%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 79.39%.

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent research reports. Bank of America cut Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price objective on the stock. in a report on Thursday, May 1st. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price objective for the company. in a research report on Friday, May 2nd. William Blair lowered shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Thursday, May 1st. Piper Sandler downgraded shares of Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and cut their price target for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Finally, Raymond James cut shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Friday, May 2nd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $231.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.